The CCNL1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-engineered polyclonal knockout population featuring targeted disruption of the CCNL1 gene in the human HeLa cell line. This product provides a heterogeneous cell pool for conducting Cyclin L1 loss-of-function studies, thereby reducing single-cell clonal artifacts. The polyclonal format is particularly advantageous for population-based assays such as high-throughput chemical screens or pooled functional genomics, where a diversity of editing events mitigates the risk of idiosyncratic phenotypes. Researchers can rely on this model to probe CCNL1-dependent mechanisms without the constraints of a clonal isolate.
HeLa cells are an immortalized human cervical epithelial cell line derived from an HPV18-positive adenocarcinoma. The expression of viral oncoproteins E6 and E7 leads to the inactivation of the tumor suppressors p53 and Rb, respectively, establishing a robust oncogenic background. This widely adopted model offers rapid proliferation, ease of genetic manipulation, and a well-annotated transcriptome, making it ideal for dissecting gene function in cancer biology.
The CCNL1 gene encodes Cyclin L1, an atypical cyclin that forms a complex with the kinase CDK11. This complex plays a pivotal role in coupling transcription with pre-mRNA splicing by directly interacting with RNA polymerase II and recruiting splicing factors such as SF2/ASF to nascent transcripts. Consequently, CCNL1 influences the alternative splicing of genes involved in apoptosis and cell cycle regulation. Although upstream regulators of CCNL1 are largely uncharacterized, its downstream targets include apoptosis-related genes and cell cycle regulators, positioning it as a critical integrator of splicing and cell fate decisions.
In the context of HeLa cells, CCNL1 knockout provides a unique window into splicing-dependent phenotypes in an HPV-transformed cervical cancer model. Disruption of Cyclin L1 is expected to alter the splicing pattern of key transcripts, potentially compromising apoptosis execution and cell cycle checkpoint fidelity. This model is particularly relevant for understanding how viral oncoproteins exploit splicing regulation to sustain malignancy, and it offers translational insights for cancers and neurodegenerative disorders where CCNL1 dysregulation is implicated.
Experimental applications of these cells are broad and include transcriptome-wide splicing analysis via RNA-seq and targeted isoform quantitation by RT-qPCR. Protein-level studies using western blotting or immunofluorescence can assess changes in splicing factor expression and localization. Functional readouts such as apoptosis assays and cell cycle analysis reveal phenotypic consequences of CCNL1 loss, while co-immunoprecipitation enables validation of the CCNL1?CCDK11 interaction. These tools are valuable for cancer biology research, drug target validation, and mechanistic dissection of RNA processing. For additional information, please contact Ascent Research.
